1. Home
  2. KPTI vs OPI Comparison

KPTI vs OPI Comparison

Compare KPTI & OPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • OPI
  • Stock Information
  • Founded
  • KPTI 2008
  • OPI 2009
  • Country
  • KPTI United States
  • OPI United States
  • Employees
  • KPTI N/A
  • OPI N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • OPI Real Estate Investment Trusts
  • Sector
  • KPTI Health Care
  • OPI Real Estate
  • Exchange
  • KPTI Nasdaq
  • OPI Nasdaq
  • Market Cap
  • KPTI 103.5M
  • OPI 105.1M
  • IPO Year
  • KPTI 2013
  • OPI 2009
  • Fundamental
  • Price
  • KPTI $0.64
  • OPI $1.02
  • Analyst Decision
  • KPTI Strong Buy
  • OPI Buy
  • Analyst Count
  • KPTI 4
  • OPI 2
  • Target Price
  • KPTI $5.00
  • OPI $4.30
  • AVG Volume (30 Days)
  • KPTI 1.0M
  • OPI 1.5M
  • Earning Date
  • KPTI 11-05-2024
  • OPI 02-13-2025
  • Dividend Yield
  • KPTI N/A
  • OPI 3.67%
  • EPS Growth
  • KPTI N/A
  • OPI N/A
  • EPS
  • KPTI N/A
  • OPI N/A
  • Revenue
  • KPTI $148,442,000.00
  • OPI $517,514,000.00
  • Revenue This Year
  • KPTI $6.67
  • OPI N/A
  • Revenue Next Year
  • KPTI $8.58
  • OPI N/A
  • P/E Ratio
  • KPTI N/A
  • OPI N/A
  • Revenue Growth
  • KPTI 1.77
  • OPI N/A
  • 52 Week Low
  • KPTI $0.63
  • OPI $1.02
  • 52 Week High
  • KPTI $1.95
  • OPI $7.53
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 25.28
  • OPI 29.66
  • Support Level
  • KPTI $0.75
  • OPI $1.32
  • Resistance Level
  • KPTI $0.83
  • OPI $1.99
  • Average True Range (ATR)
  • KPTI 0.05
  • OPI 0.10
  • MACD
  • KPTI -0.01
  • OPI -0.03
  • Stochastic Oscillator
  • KPTI 4.21
  • OPI 0.00

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About OPI Office Properties Income Trust of Beneficial Interest

Office Properties Income Trust is a United States-based real estate investment trust. Its property portfolio is mainly composed of single-tenant office buildings, as well as multitenant properties, which are leased to parties of high credit quality characteristics. Its largest tenant is the U.S. government, followed by other smaller government entities and corporations. The company's properties are spread across the United States. The company has only one segment which is direct ownership of real estate properties.

Share on Social Networks: